Sign in
CompletedPhase 3

Bismuth Quadruple Therapy Versus Modified Bismuth Therapy for Helicobacter Pylori

Key facts

Who runs it
Reham Abdelkader Elkhouly
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
200 people enrolled
Started
1 Sept 2023
Ended
1 Sept 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Bismuth added on triple therapy
  • Quadruple therapy
Record updated
11 September 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Patients aged ≥ 18 years
  • Confirmed diagnosis of H. pylori infection

Who cannot take part

  • Prior treatment for H. pylori infection
  • Presence of any contraindication to the study medications
  • History of antibiotic or PPI use within the month preceding enrollment
  • History of hypersensitivity or allergic reaction to any of the study drugs
  • Advanced chronic liver disease or renal disease
  • Pregnant or lactating women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of the study is to compare the efficacy of 2 different regimens of treatment of gastric bacteria (H pylori) these are: quadruple bismuth therapy and clarithromycin triple therapy with add-on bismuth, in eradicating H. pylori.

Read full original descriptionShow less

The secondary objective of the study is detection of adverse effects and treatment compliance in both regimens.

The 2 groups in the trial

  • Bismuth added on triple therapyTreatment being tested

    100 patients received oral triple therapy with add-on bismuth in the form of (Bismuth subcitrate 240 mg twice daily, Clarithromycin 500 mg twice daily, Amoxicillin 1gm twice daily, (PPI) Esomeprazole 40 mg twice daily for 2 weeks).

  • bismuth quadruple therapyExisting treatment, for comparison

    100 patients received 14-day oral regimen comprising Bismuth subcitrate (240 mg twice daily), Doxycycline (100 mg twice daily), Metronidazole (500 mg three times daily), and Esomeprazole (40 mg twice daily).

    Treatment: Quadruple therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Eradication of Helicobacter Pylori: A Comparative Randomized Controlled Trial of Bismuth Quadruple Therapy and Bismuth Add-on to Clarithromycin Triple Therapy
Record updated
11 September 2026